Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Recurrence 2 Osteosarcoma 2 Sarcoma, Kaposi 1 Rhabdomyosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Glioma 1 GIST 1 Central Nervous System Neoplasms 1 Bone Neoplasms 1

Interventions

Doxorubicin 25 Radiotherapy 16 Ifosfamide 14 Trabectedin 10 pazopanib 6 ribociclib 5 pembrolizumab 5 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Biopsy 5 palbociclib 4 Radiation 4 Docetaxel 4 Chemotherapy, Adjuvant 4 selinexor 3 liposomal doxorubicin 3 eribulin 3 abemaciclib 3 X-Rays 3 Vincristine 3 Neoadjuvant Therapy 3 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 toripalimab 2 temsirolimus 2 romidepsin 2 pegfilgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × lenvatinib × Sarcoma × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡